1151665-15-4

Usage

Uses

Used in Pharmaceutical Industry:
Tert-Butyl 2-chloro-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate is used as an intermediate in the production of pharmaceuticals for its ability to be incorporated into the synthesis of various drug molecules. Its unique structure allows for the development of new compounds with potential therapeutic properties.
Used in Agrochemical Industry:
In the agrochemical industry, tert-Butyl 2-chloro-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate is used as a precursor in the synthesis of agrochemicals. Its chemical properties make it suitable for the development of new compounds with pesticidal or herbicidal activities, contributing to more effective crop protection.
Used in Organic Synthesis:
Tert-Butyl 2-chloro-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate is utilized as a building block in organic synthesis. Its reactivity and structural features enable the creation of a wide range of chemical compounds for various applications, including the development of new materials, dyes, and other specialty chemicals.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, tert-Butyl 2-chloro-7,8-dihydro-1,6-naphthyridine-6(5H)-carboxylate serves as a valuable research tool. Its unique structure allows scientists to explore its potential as a scaffold for the design of new drugs, as well as to study its interactions with biological targets and its pharmacological properties.

Upstream product

• 210539-04-1 6-benzyl-2-chloro-5,6,7,8-tetrahydro-1,6-naphthyridine 
• 24424-99-5 di-tert-butyl dicarbonate 
• 210539-05-2 2-chloro-5,6,7,8-tetrahydro-1,6-naphthyridine 
• 601514-58-3 6-benzyl-5,6,7,8-tetrahydro-[1,6]-naphthyridin-2(1H)-one 
• 23616-29-7 1,6-naphthyridin-2(1H)-one 
• 766545-20-4 2-chloro-5,6,7,8-tetrahydro[1,6]naphthyridine hydrochloride 

Downstream Products

• 1346673-94-6 tert-butyl 2-[(diphenylmethylidene)amino]-5,6,7,8-tetrahydro-1,6-naphthyridine-6-carboxylate 
• 1036381-91-5 tert‐butyl 2‐oxo‐1,5,7,8‐tetrahydro‐1,6‐naphthyridine‐6(2H)‐carboxylate 
• 259809-47-7 6-(tert-butoxycarbonyl)-2-methoxycarbonyl-5,6,7,8-tetrahydro-1,6-naphthyridine 
• 1868106-31-3 tert-butyl 2-(hydroxymethyl)-7,8-dihydro-5H-1,6-naphthyridine-6-carboxylate 
• 1149333-40-3 2-amino-7,8-dihydro-1,6-naphthyridin-6(5H)-carboxylic acid tert-butyl ester 
• 210539-05-2 2-chloro-5,6,7,8-tetrahydro-1,6-naphthyridine 

Relevant academic research and scientific papers

HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS

Heterocyclic compounds as CDK4 or CDK6 or other CDK inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

Compounds and methods of use

Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X1, X2, X3, X4, Y, A, L1, L2, R1, R2, R5, m and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.

N-(PHENYLAMINOCARBONYL) TETRAHYDRO-ISOQUINOLINES AND RELATED COMPOUNDS AS MODULATORS OF GPR65

The present invention relates to a compound of formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, (I) wherein: ring A is a 5- or 6-membered monocyclic aromatic or heteroaromatic ring, or a 9- or 10-membered bicyclic aromatic or hetero

BICYCLIC DERIVATIVES AS GABAA Α5 RECEPTOR MODULATORS

The present invention provides compounds of formula (I) and/or salt thereof and/or geometric isomer thereof and/or stereoisomer thereof and/or enantiomer thereof and/or racemate thereof and/or diastereomer thereof and/or biologically active metabolite thereof and/or prodrug thereof and/or solvate thereof and/or hydrate thereof and/or polymorph thereof having affinity and selectivity for the gamma-aminobutyric acid A receptor subunit alpha 5 and act as GABAA α5 negative allosteric modulators, thereby useful in the treatment or prevention of diseases related to the GABAA α5 receptor, process for the preparation thereof, pharmaceutical compositions comprising them alone or in combination with one or more other active ingredients and their use as medicaments.

Method for synthesizing 5, 6, 7, 8 - tetrahydro -1, 6 - naphthyridine -2 amine

The invention discloses a synthesis method of 5,6,7,8-tetrahydro-1,6-naphthyridine-2-amine. The synthesis method comprises the specific steps: (1) carrying out amino protection reaction on 2-halo-5,6,7,8-tetrahydro-1,6-naphthyridine to prepare 6-site-protected 2-halo-5,7,8-trihydro-1,6-naphthyridine; (2) carrying out palladium-catalyzed coupling reaction on the 6-site-protected 2-halo-5,7,8-trihydro-1,6-naphthyridine and carbamate under basic conditionsto prepare double-site-protected 5,7,8-trihydro-1,6-naphthyridine-2-amine; (3) carrying out deprotection reaction on the double-site-protected 5,7,8-trihydro-1,6-naphthyridine-2-amine to prepare 5,6,7,8-tetrahydro-1,6-naphthyridine-2-amine. In the whole technical process, only conventional reagents are used, the use of azides with high toxicity and environmental hazards is avoided, reaction conditions are mild and the method is safer and more environmentally friendly.

CDK4/6 INHIBITORS AND USE THEREOF

The present disclosure relates to a compound of formula (I), or a pharmaceutically acceptable salt, a solvate, a stereoisomer, or tautomer thereof, a pharmaceutical composition comprising a compound of formula (A) or formula (B), and any subgenera thereof, and use of said compounds and compositions thereof, wherein R1, R2, R3a, R3b, R5, R6, X1, X2, Y and n are described herein.

ANTI-PULMONARY TUBERCULOSIS NITROIMIDAZOLE DERIVATIVE

Disclosed is a substituted nitroimidazole derivative, which is mainly used for treating related diseases caused by mycobacterial infections, such as Mycobacterium tuberculosis, especially being suitable for diseases caused by resistant Mycobacterium tuberculosis.

Compound of CDK small-molecule inhibitor and application thereof

The invention relates to a novel compound used as a CDK small-molecule inhibitor and application thereof, and relates to a medicine composition comprising the compound, and application of the compound and the composition to treatment of diseases of excessive proliferative disorder. The formula of the compound is shown in the formula (I) (in the description). The new compound is a powerful cyclin-dependent kinases 4 (cdk4) inhibitor or a cyclin-dependent kinases 6 (cdk6) inhibitor.

Discovery of AMG 925, a FLT3 and CDK4 dual kinase inhibitor with preferential affinity for the activated state of FLT3

We describe the structural optimization of a lead compound 1 that exhibits dual inhibitory activities against FLT3 and CDK4. A series of pyrido[4′,3′:4,5]pyrrolo[2,3-d]pyrimidine derivatives was synthesized, and SAR analysis, using cell-based assays, led to the discovery of 28 (AMG 925), a potent and orally bioavailable dual inhibitor of CDK4 and FLT3, including many FLT3 mutants reported to date. Compound 28 inhibits the proliferation of a panel of human tumor cell lines including Colo205 (Rb +) and U937 (FLT3WT) and induced cell death in MOLM13 (FLT3ITD) and even in MOLM13 (FLT3ITD, D835Y), which exhibits resistance to a number of FLT3 inhibitors currently under clinical development. At well-tolerated doses, compound 28 leads to significant growth inhibition of MOLM13 xenografts in nude mice, and the activity correlates with inhibition of STAT5 and Rb phosphorylation.

NEW BICYCLIC DIHYDROISOQUINOLINE-1-ONE DERIVATIVES

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4? R5, R6, A1, A2, A3, A4, A5 and n are as described herein,compositions including the compounds and methods of using the compounds as aldosterone synthase (CYP11B2 or CYP11B1) inhibitors for the treatment or prophylaxis of chronic kidney disease, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrom.